Company news

Stoke Therapeutics, Inc. news in 2023

Stoke Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting

November 30, 2023

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting

November 20, 2023

Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

September 20, 2023

Stoke Therapeutics Appoints Ian Smith to its Board of Directors

September 19, 2023

Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress

September 4, 2023

Stoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference

August 1, 2023

Stoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome

July 24, 2023

Stoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet Syndrome

July 20, 2023

Stoke Therapeutics to Present at the BofA Securities Health Care Conference

May 2, 2023

Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United Kingdom

April 24, 2023

Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome

March 14, 2023

Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

March 5, 2023

Stoke Therapeutics to Participate at Upcoming March Investor Conferences

February 26, 2023

Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference

February 6, 2023

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023

January 8, 2023

Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Decks in 2023